CH678492A5 - - Google Patents

Download PDF

Info

Publication number
CH678492A5
CH678492A5 CH3632/88A CH363288A CH678492A5 CH 678492 A5 CH678492 A5 CH 678492A5 CH 3632/88 A CH3632/88 A CH 3632/88A CH 363288 A CH363288 A CH 363288A CH 678492 A5 CH678492 A5 CH 678492A5
Authority
CH
Switzerland
Prior art keywords
tumor
pyridine
mpl
microorganism
cell wall
Prior art date
Application number
CH3632/88A
Other languages
German (de)
English (en)
Inventor
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of CH678492A5 publication Critical patent/CH678492A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CH3632/88A 1987-09-30 1988-09-30 CH678492A5 (forum.php)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/102,909 US4877611A (en) 1986-04-15 1987-09-30 Vaccine containing tumor antigens and adjuvants

Publications (1)

Publication Number Publication Date
CH678492A5 true CH678492A5 (forum.php) 1991-09-30

Family

ID=22292343

Family Applications (1)

Application Number Title Priority Date Filing Date
CH3632/88A CH678492A5 (forum.php) 1987-09-30 1988-09-30

Country Status (10)

Country Link
US (1) US4877611A (forum.php)
JP (1) JPH01163130A (forum.php)
BE (1) BE1001634A4 (forum.php)
CA (1) CA1333152C (forum.php)
CH (1) CH678492A5 (forum.php)
DE (1) DE3833319A1 (forum.php)
FR (1) FR2620941B1 (forum.php)
GB (1) GB2210557B (forum.php)
IT (1) IT1226861B (forum.php)
NL (1) NL8802393A (forum.php)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
EP0420848B1 (en) * 1987-12-09 1996-02-07 The General Hospital Corporation Carcinoma-associated antigens, and antibodies which recognize these antigens
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
ES2019728A6 (es) * 1988-09-23 1991-07-01 Univ Southern California Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
US4963364A (en) * 1989-04-10 1990-10-16 Fox Sidney W Microencapsulated antitumor agent
CA2055441C (en) * 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
US6177083B1 (en) * 1990-07-26 2001-01-23 Evax Technologies Gmbh Process for the production of vaccines and their use
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
EP0472467A3 (en) * 1990-08-20 1993-03-17 Chiba Flour Milling Co. Ltd. Lps-containing analgesics and veterinary analgesics
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
WO1994000153A1 (en) * 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
WO1994021297A1 (en) * 1993-03-16 1994-09-29 Samuel Bogoch Recognin vaccines
ES2109685T5 (es) * 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
EP0721345B1 (en) * 1993-08-11 2005-08-31 Jenner Technologies Prostatic cancer vaccine
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
USD365131S (en) 1994-05-25 1995-12-12 Royal Grip, Inc. Golf club grip
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US6303584B1 (en) 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
NZ502674A (en) 1997-08-05 2002-06-28 Bioniche Life Sciences Inc Composition comprising Mycobacterial phlei DNA and/or cell wall extract from M. phlei for treating cancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
EP1097715A4 (en) * 1998-07-16 2004-12-29 Hayashi Akira PREPARATIONS FOR ANTICANCER IMMUNOTHERAPY COMPRISING A BACTERIAL SOMATIC COMPONENT AS AN ACTIVE INGREDIENT
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
MXPA01005813A (es) 1998-12-08 2002-05-06 Corixa Corp Compuestos y metodos para tratamiento y diagnostico de infeccion por clamidia.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
JP2002543769A (ja) 1999-04-02 2002-12-24 コリクサ コーポレイション 肺癌の治療および診断のための化合物および方法
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7311922B1 (en) * 1999-10-07 2007-12-25 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
PT1238070E (pt) * 1999-12-13 2007-11-06 Bioniche Life Sciences Inc Oligonucleótidos sintéticos úteis sob o ponto de vista terapêutico
DK1250152T3 (da) * 1999-12-28 2013-08-26 Bioniche Urology Ip Inc Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
DK1265915T3 (da) 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa Nye forbindelser
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ES2303525T3 (es) 2000-04-21 2008-08-16 Corixa Corporation Compuestos y metodos para el tratamiento y diagnostico de infeccion por chlamydia.
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
AU2001269695B2 (en) 2000-05-19 2007-02-15 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1961819A3 (en) 2000-06-28 2008-11-12 Corixa Corporation Composition and methods for the therapy and diagnosis of lung cancer
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
AU2002354644C1 (en) 2001-07-10 2009-04-30 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
PL207168B1 (pl) * 2001-09-20 2010-11-30 Glaxo Group Ltd Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040033213A1 (en) * 2002-02-28 2004-02-19 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP1523582B1 (en) 2002-07-18 2008-11-12 University of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
AU2003290825C1 (en) 2002-11-13 2009-12-10 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
CN101080234A (zh) 2003-01-06 2007-11-28 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1713900A4 (en) * 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Ｍｂｒ 細菌細胞壁骨格成分を含有する製剤
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
WO2006042156A2 (en) 2004-10-08 2006-04-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Modulation of replicative fitness by using less frequently used synonymous codons
US7332324B2 (en) 2004-12-03 2008-02-19 University Of Toledo Attenuated vaccine useful for immunizations against Coccidioides spp. infections
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
UA97943C2 (ru) 2005-03-31 2012-04-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против инфекции chlamydia
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
BRPI0617486A2 (pt) 2005-10-18 2011-07-26 Novavax Inc vacina que compreende partÍculas similares a vÍrus da gripe funcionais (vlp) e uso de uma vlp de gripe
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5578390B2 (ja) * 2007-03-05 2014-08-27 株式会社 Ｍｂｒ 細菌細胞壁骨格成分の製造方法
ES2621211T3 (es) 2007-04-04 2017-07-03 Infectious Disease Research Institute Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP3539567A1 (en) 2007-07-02 2019-09-18 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2009128936A2 (en) 2008-04-16 2009-10-22 The Johns Hopkins University Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
US20110177117A1 (en) * 2008-07-18 2011-07-21 Normand Blais Chimeric respiratory syncytial virus polypeptide antigens
WO2010058023A1 (en) 2008-11-24 2010-05-27 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity t cell receptor and use thereof
BRPI0916489B1 (pt) 2008-11-26 2021-11-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Partícula do tipo vírus (vlp), composição imunogênica, vacina e uso
CA2746228C (en) 2008-12-09 2021-05-18 Novavax, Inc. Modified rsv f proteins and methods of their use
US9265821B2 (en) 2009-02-17 2016-02-23 Glaxosmithkline Biologicals Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
EP2451950B9 (en) 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
KR101125764B1 (ko) 2010-01-27 2012-03-27 백태현 항산균 세포벽골격을 이용한 백신매개체 및 그에 의한 백신의 제조 방법
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
PT2588133T (pt) * 2010-07-02 2018-03-05 Intervet Int Bv Vacina contra ehrlichia canis e métodos associados
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
MA34802B1 (fr) 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
LT2635257T (lt) 2010-11-05 2017-09-25 Novavax, Inc. Pasiutligės glikoproteino į virusą panašios dalelės (vlps)
WO2012064659A1 (en) 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
EP3593813A1 (en) 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenic composition
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
PT3275892T (pt) 2011-05-13 2020-04-08 Glaxosmithkline Biologicals Sa Antigénios f de rsv de pré-fusão
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
BR112014023092A8 (pt) 2012-03-18 2017-07-25 Glaxosmithkline Biologicals Sa Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP4299138A3 (en) 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
HUE061273T2 (hu) 2012-12-05 2023-06-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
KR102450375B1 (ko) 2013-03-13 2022-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3632458B1 (en) 2013-07-26 2025-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2015018806A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
US10751410B2 (en) 2013-09-19 2020-08-25 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3186393A4 (en) 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CN113456812B (zh) 2015-01-09 2024-08-20 埃图比克斯公司 用于联合免疫治疗的方法和组合物
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016191553A1 (en) 2015-05-26 2016-12-01 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
US20170226171A1 (en) * 2016-02-09 2017-08-10 Vaccinogen, Inc. Adenocarcinoma antigenic determinants and methods
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
EP3735984A1 (en) 2016-05-27 2020-11-11 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
MX2019006728A (es) 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
MX2019006349A (es) 2016-12-16 2019-08-22 Inst Res Biomedicine Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IL269904B1 (en) 2017-04-19 2025-06-01 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
US11591364B2 (en) 2017-12-01 2023-02-28 Glaxosmithkline Biologicals Sa Saponin purification
WO2019147925A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
CN112292185B (zh) 2018-04-17 2025-07-29 塞德斯医疗公司 抗cd27和抗pd-l1抗体及双特异性构建体
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
JP2021532764A (ja) 2018-07-31 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原精製方法
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
WO2020163875A1 (en) * 2019-02-08 2020-08-13 University Of Florida Research Foundation, Inc. A monophosphoryl lipid-a liposome based cancer vaccine
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4028051A1 (en) 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
CA3155424A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
EP4077356A1 (en) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA S. aureus antigens and compositions thereof
SI4090363T1 (sl) 2020-01-16 2024-10-30 Janssen Pharmaceuticals, Inc. FIMH mutant, njegovi sestavki in njihova uporaba
WO2021178637A1 (en) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021214766A1 (en) 2020-04-21 2021-10-28 Yeda Research And Development Co. Ltd. Methods of diagnosing viral infections and vaccines thereto
EP4146378A1 (en) 2020-05-05 2023-03-15 GlaxoSmithKline Biologicals S.A. Microfluidic mixing device and methods of use
EP4158352A1 (en) 2020-06-01 2023-04-05 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
AU2021392894B2 (en) 2020-12-02 2024-09-19 Glaxosmithkline Biologicals Sa Donor strand complemented fimh
JP2023553904A (ja) 2020-12-09 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン
JP2024500245A (ja) 2020-12-24 2024-01-05 プラント・バイオサイエンス・リミテッド 方法および組成物
JP7532672B2 (ja) 2021-01-12 2024-08-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、それを含む組成物、及びその使用
CN117222428A (zh) 2021-02-11 2023-12-12 葛兰素史克生物有限公司 Hpv疫苗生产
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
US20250207166A1 (en) 2022-03-25 2025-06-26 Plant Bioscience Limited Biosynthesis
JP2025525334A (ja) 2022-06-15 2025-08-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンの酵素的修飾
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (forum.php) * 1971-11-19 1975-02-07 Anvar
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505903A (en) * 1982-06-30 1985-03-19 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use

Also Published As

Publication number Publication date
DE3833319A1 (de) 1989-04-13
DE3833319C2 (forum.php) 1992-06-11
BE1001634A4 (fr) 1990-01-02
CA1333152C (en) 1994-11-22
NL8802393A (nl) 1989-04-17
FR2620941A1 (fr) 1989-03-31
FR2620941B1 (fr) 1990-08-10
JPH01163130A (ja) 1989-06-27
GB2210557A (en) 1989-06-14
US4877611A (en) 1989-10-31
IT1226861B (it) 1991-02-19
GB8822749D0 (en) 1988-11-02
GB2210557B (en) 1991-11-13
IT8822145A0 (it) 1988-09-30
JPH0575731B2 (forum.php) 1993-10-21

Similar Documents

Publication Publication Date Title
DE3833319C2 (forum.php)
DE3318567C2 (de) Therapeutisches Mittel, enthaltend gereinigtes, entgiftetes Endotoxin, Zellwandgerüst und Trehalosedimycolat
DE3712768C2 (forum.php)
DE69116377T2 (de) Mycobacterium vaccae in der behandlung von uveitis
DE3318569A1 (de) Verfahren zur herstellung von gereinigtem, entgiftetem endotoxin
DE3434766C2 (de) Pharmazeutisches Präparat
DE69418183T2 (de) Immunotherapeutische zubereitung
DE2908241A1 (de) Bakterienzellenextrakt, verfahren zu seiner herstellung, diesen bakterienzellenextrakt enthaltende antitumoraktive zubereitung und adjuvanspraeparat
US4520019A (en) Stable composition and preparation thereof
DE69526935T2 (de) Verwendung von mycobacterium zur tumorbehandlung
DE3318568A1 (de) Therapeutische zusammensetzung enthaltend gereinigtes, entgiftetes endotoxin, trehalosedimycolat und ein mit azeton ausgefaelltes nebenprodukt von mit chloroform-methanol extrahierten endotoxischen glykolipiden
DE60031100T2 (de) Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung
DE2735411A1 (de) Verfahren zur herstellung von acellulaeren vaccinen und nach diesem verfahren gewonnene vaccine
DE2547105A1 (de) N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien
Gray et al. Brief Communication: Immunotherapy of Cancer: Tumor Suppression and Regression by Cell Walls of Mycobacterium phlei Attached to Oil Droplets
US4504473A (en) Pyridine soluble extract of a microorganism
DE2325299A1 (de) Aus mikroorganismen von der art der mycobakterien erhaltene, nicht-spezifische reizmittel, die eine antitumorimmunitaet hervorrufen und verfahren zu deren herstellung
CH641354A5 (de) Material mit antitumorwirkung und verfahren zu dessen herstellung.
DE2834893C2 (forum.php)
EP0445710A1 (de) Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen
DE60213785T2 (de) Saponin inaktivierte mykoplasma impfstoffe
DE2829975A1 (de) Antitumor wirksame substanz, deren herstellung und verwendung
DE69430858T2 (de) Anti-Aids Immunomodulatorkomplex
DE3323092C2 (de) Pharmazeutisches Präparat
DE3323093C2 (de) Pharmazeutisches Präparat zur Bekämpfung von Tumoren

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: RIBI IMMUNOCHEM RESEARCH, INC.

Free format text: RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US) -TRANSFERTO- RIBI IMMUNOCHEM RESEARCH, INC.#N.E. 581 OLD CORVALLIS ROAD P.O. BOX 1409#HAMILTON/MT (US)

PL Patent ceased